Autolus Therapeutics (AUTL) to Release Quarterly Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL) will be issuing its quarterly earnings data before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.76) per share for the quarter.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.11). The business had revenue of $1.96 million during the quarter, compared to the consensus estimate of $0.30 million. On average, analysts expect Autolus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Autolus Therapeutics stock traded up $0.13 on Tuesday, reaching $14.25. The company’s stock had a trading volume of 1,279 shares, compared to its average volume of 130,611. The company has a debt-to-equity ratio of 0.12, a quick ratio of 10.66 and a current ratio of 10.66. The stock has a market capitalization of $600.18 million, a P/E ratio of -10.04 and a beta of 0.40. The company’s fifty day moving average is $15.57. Autolus Therapeutics has a twelve month low of $12.70 and a twelve month high of $53.24.

A number of equities analysts have commented on AUTL shares. Zacks Investment Research raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. ValuEngine raised Autolus Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $41.00 price objective (down previously from $45.00) on shares of Autolus Therapeutics in a research note on Friday, May 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Autolus Therapeutics currently has an average rating of “Buy” and an average target price of $45.50.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with's FREE daily email newsletter.